Inclusion Criteria:

1. Be 18 years of age or older at the time of signing the informed consent form.

2. The subject himself voluntarily participates in the study, signs the informed
consent form, and can provide legal identification, understand and comply with the
requirements of the research protocol.

3. More than 6 months after completing the basic immunization or booster immunization
of the new coronavirus vaccine.

4. Female subjects of childbearing age and male subjects who were able to use effective
contraception during the study.

Exclusion Criteria:

Participants were not eligible for study if they had any of the following:

1. Previous history of severe allergy to any vaccine, or history of severe allergy to
any component of the study vaccine, including aluminum preparations, such as:
anaphylactic shock, allergic laryngeal edema, Henoch-Schönlein purpura,
thrombocytopenic purpura, dyspnea, angioedema, allergic constitution (such as
allergy to two or more drugs, food or pollen), etc.

2. fever (axillary body temperature≥ 37.3°C) within 72 hours before enrollment, or
axillary body temperature ≥ 37.3°C on the day of enrollment.

3. Patients infected with the new coronavirus within 3 months before enrollment
(asymptomatic infection or positive nucleic acid or antigen test of the new
coronavirus).

4. Patients with aplastic anemia that has not been relieved, primary immune
thrombocytopenia (ITP) active period, and uncontrolled coagulation diseases.

5. history of congenital or acquired immunodeficiency or autoimmune disease; no history
of spleen or spleen surgery or trauma; or receive immunomodulators within 6 months,
such as corticosteroids in immunosuppressant doses (dose reference: equivalent to
prednisone 20 mg/day for more than one week); or monoclonal antibodies; or thymus
peptide; or interferon, etc.; However, topical medications (such as ointments, eye
drops, inhalers, or nasal sprays) are allowed; Lymphoproliferative disorders are not
controlled.

6. Non-live vaccine ≤ 14 days before vaccination and live attenuated vaccine 30 days
before ≤vaccination.

7. Patients with malignant tumors who are undergoing chemotherapy, radiotherapy,
immunotherapy, etc. before and after surgery, Patients in the state of organ
transplantation.

8. Those suffering from uncontrolled epilepsy and other progressive neurological
diseases (such as transverse myelitis, Guillain-Barre syndrome, demyelinating
diseases, etc.).

9. Patients with acute diseases, or acute exacerbations of chronic diseases, or
uncontrolled severe chronic diseases, such as hypertension that cannot be controlled
by drugs (systolic blood pressure ≥ 160mmHg and/or diastolic blood pressure
≥100mmHg).

10. Lactating women or pregnant women; The investigator believes that the participant
has any disease or condition that would put the participant at risk, the participant
cannot complete the study as required by the protocol, and there are circumstances
that interfere with the assessment of vaccine response.